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A BST R AC T   
 
Aim: COVID-19 infections the tissue through angiotensin converting enzyme 2 receptor, which is also 
expressed on endothelial cells. Endothelial dysfunction may be associated with lung involvement. Asymmetric 
dimethylarginine (ADMA) is an indirect marker of endothelial dysfunction. The aim of our study was to 
evaluate ADMA concentrations and to identify its association with lung involvement in patients with COVID-
19 disease. 
Methods: We included 42 patients with COVID-19 infection and lung involvement (Group 1). Forty-two age 
and sex matched patients without pneumonia acted as the control group (Group 2). All patients gave blood 
samples for ADMA at the 1st month control visit after discharge. We compared C-reactive protein (CRP) and 
ADMA concentrations in addition to routine biochemical parameters between groups. 
Results: Patients with lung involvement had higher admission glucose, CRP, and ADMA concentrations, and 
displayed lower hemoglobin concentration and lymphocyte count compared to patients without lung 
involvement. Although patients with lung involvement had higher ADMA concentrations with respect to those 
without; plasma ADMA levels were also higher than normal values in control group. Multivariate analysis 
identified log CRP concentration (OR= 3.047, 95% CI=1.881-5.023, p<0.001) as the independent predictor 
for lung involvement. And, there was a correlation between ADMA and CRP (r: 0.318, p: 0.003). 
Conclusion: We revealed elevated ADMA concentrations as the surrogate of endothelial dysfunction in 
COVID-19 patients whether they have pneumonia or not. 
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Introduction 
SARS-CoV-2 infection, also nominated as 
Coronaviral Disease 2019 (COVID-19), was 
characterized as a pandemic since March 2020 
by World Heart Organization [1].  The number 
of cases and mortality has increased gravely 
ever since [2]. Although the majority of patients 
tend to be well or asymptomatic, 14% 
experience severe, and 5% suffer critical 
disease with lung involvement [3].  
Interestingly several cardiovascular co-
morbidities have been identified to be 
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associated with a higher rate of pulmonary 
complications. 
COVID-19 infects the tissue thorough 
angiotensin converting enzyme 2 receptor. This 
receptor is abundantly expressed in endothelial 
cells besides lung, heart, kidney and bowel 
tissue [4]. The infection of endothelial lining 
may induce endothelial dysfunction, which 
may be in part responsible for multi-systemic 
involvement. Endothelial dysfunction can be 
assessed by several invasive or non-invasive 
methods [5]. Nitric oxide (NO), synthesized by 
the endothelial nitric oxide synthase, is a 
multifunctional molecule involved in 
vasodilation, and the immune system. NO has 
additional activity in cytokine secretion, non-
specific immunity, inhibition of viral 
replication, and transplant rejection [6,7]. 
Asymmetric dimethylarginine (ADMA) is an 
inhibitor of endogenous nitric oxide synthase. 
Since serum ADMA concentration is inversely 
related with nitric oxide synthesis, ADMA 
concentration may be an indirect marker of 
endothelial dysfunction. Moreover, ADMA is 
non-invasive, cheap and a practical measure for 
detecting endothelial dysfunction. 
As we have witnessed a global pandemic in the 
past months, identification co-morbidities and 
predictors associated with more frequent lung 
involvement and higher mortality is essential. 
We hypothesized that ADMA concentrations 
reflecting endothelial dysfunction might be 
related to lung involvement in this specific 
patient group. So, this study planned to 
investigate ADMA concentrations in patients 
with COVID-19 infection 
 
Materials and methods 
Study Design & Demographics 
Our study, prospective, and observational 
cross-sectional cohort in-design, included 
consecutive 42 patients with COVID-19 
infection and lung involvement (Group 1). Age 
and sex matched consecutive 42 COVID-19 
patients without pneumonia acted as the control 
group (Group 2). Assuming an alpha of 0.05, a 
power of 0.80, and 30% potential change from 
baseline value in terms of pulmonary 
involvement consistent with previous reports, 
the estimated sample size was at least 40 
patients in total.  
All patients were informed about the study and 
their written consent was given. The research 
was realized in accordance with the principles 
set by the Declaration of Helsinki, the 
International Good Clinical Practice guidelines 
and all applicable legal requirements. The study 
protocol was approved with registration 
number of 2020/164 by Recep Tayyip Erdoğan 
University School of Medicine Ethics 
Committee.  
Patients who did not have any lung pathology 
at onset and got lung involvement in the follow-
up period were included in the first group. 
Diagnosis of COVID-19 was proven using 
polymerase chain reaction (PCR) method 
and/or computed tomography (CT). Medication 
history including previous and novel 
medications throughout hospitalization were 
recorded.  
We excluded patients with immunosuppressive 
treatment, renal or hepatic failure, malignancy, 
idiopathic pulmonary fibrosis, and patients who 
passed away through follow-up. 
Following diagnosis of COVID-19 infection by 
an infectious disease expert or a pulmonologist, 
complaints, demographic and laboratory 
parameters, and CT images of the patients were 
reviewed and recorded. Diabetes mellitus was 
acknowledged as the fasting blood glucose 
concentration > 126 mg/dL or any blood 
glucose measurement >200 mg/dL or use of 
anti-diabetic medication. Hypertension was 
accepted as blood pressure above 130/85 
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mmHg or use of anti-hypertensive drugs. Those 
who smoked regularly in the last 6 months were 
denoted as smokers. 
Biochemical analysis 
Blood samples were taken for ADMA analysis 
using antecubital veins at the first month 
control of recovered patients and stored in a -
800C refrigerator after centrifugation.  Human 
ADMA Elisa kit (Cloud-Clone Corp., China) 
was used to detect serum ADMA levels. While 
assay range is indicated between 12.35 ng/mL 
and 1000 ng/mL, the intraassay and interassay 
coefficient of variations (CV) were<10%, 
<12% respectively, according to the 
manufacturer. The sensitivity of the assay was 
stated as 4.99 ng/mL by manufacturer. 
C reactive protein (CRP) levels were 
quantitated using immunoturbidimetric assay 
on Beckman Coulter AU5800 autoanalyzer 
(Beckman Coulter Diagnostics, USA). While 
the assay range for CRP was below 5 mg/L, the 
within run and total precision are less than 5% 
CV, according to the manufacturer.  
Computed tomography 
Thorax CT acquisitions were performed by 
Alexion 16 detector CT (Toshiba Medical 
Systems, Japan) machine in the supine position 
during breath-holding following deep 
inspiration from lung apices to umbilicus 
without non-ionic contrast, using the 
parameters of 120 kV, 125 mA, 16x1.5 mm 
collimation and 3 mm thickness, 512x512 
matrix. A specialized thoracic radiologist 
assessed axial views at parenchyma window 
(1500 HU, -600 HU). The images were 
transferred to a workstation to evaluate typical 
or atypical COVID-19 disease signs.  The 
patients were staged according to Radiological 
Society North America (RSNA) criteria using 
CT images of patients during hospitalization.  
Typical appearance includes highly specific 
imaging features, indeterminate appearance 
denotes non-specific features and atypical 
appearance implies uncommonly or not 
reported features of COVID-19 pneumonia. 
Negative for pneumonia shows no features of 
pneumonia. The group 1 patient mainly 
included patients with typical appearance, and 
some with indeterminate appearance. Control 
subjects were mostly negative for pneumonia 
with a few atypical appearances. 
Statistical analysis 
The Statistical Package for the Social Sciences 
20.0 statistical software program (SSPS Inc, 
Chicago, Illinois) was used for the statistical 
analysis. Kolmogorov Smirnov was used to 
check normality of continuous variables. 
Continuous variables were expressed as the 
mean ± standard deviation. Categorical 
variables were presented as percentages. The 
normally distributed variables were compared 
with the Student’s t-test and the variables that 
did not conform to a normal distribution were 
compared with Mann–Whitney U- test. 
Categorical variables were compared with chi-
square or Fisher exact test. Continuous 
variables without normal distribution were log-
transformed for univariate and multi-variate 
analysis. Linear and logistic regression 
analyses were used for the multivariate analysis 
of independent variables which were included 
if they were significantly different in the 
univariate analyses. All tests of significance 
were two-tailed. Statistical significance was 
defined as p < 0.05. 
 
Results  
We included age and gender matched 42 
COVID-19 patients to each group according to 
pneumonic involvement on CT or not.  Our 
study included 39 female and 45 male patients 
with a median age of 55 (46-69). Demographic 
characteristics of the study group are presented 
in Table 1. The patients with lung involvement  
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Table 1. Demographical and clinical findings of the study population. 
Variable Lung Involvement (-) (n=42) Lung Involvement (+) (n=42) p 
Age (Year) 54.212.8 54.111.7 0.965 
Gender (n/%) 
      Female  










BMI (kg/m2) 28.74.02 27.62.9 0.163 
SBP (mmHg) 124.612.5 122.125.9 0.558 
DBP (mmHg) 76.48.9 73.315.1 0.261 
Heart rate (bpm/min) 69.815.2 74.121.8 0.292 
LVEF (%) 60.42.7 59.63.2 0.267 
HT n% 21 (50) 22 (52.4) 0.830 
Current smoking (n/%) 6 (14.3) 6 (14.3) 1.000 
Fever ( C) 14 (33.3) 26 (61.9) 0.008 
Asymptomatic (n/%) 13 (31.0) 0 (0) <0.001 
HPL (n/%) 9 (21.4) 11826.4) 0.614 
COPD (n/%) 1 (2.4) 1 (22.4) 1.000 
Previous CAD (n/%) 3 (7.1) 6 (14.3) 0.296 
B. Blocker (Adm) (n/%) 6 (14.3) 12 (28.6) 0.113 
CCB (Adm) (n/%) 5 (11.9) 7 (16.7) 0.539 
ACEI (Adm) (n/%) 4 (9.5) 8 (19.0) 0.217 
ARB (Adm) (n/%) 10 (23.8) 8819) 0.600 
Statin therapy (Adm) (n/%) 8 (19) 10(23.8) 0.600 
Glucose (Adm) (mg/dL) 107.422.5 133.660 0.011 
Se Cr (mg/dL) 0.860.33 0.810.18 0.352 
CRP (mg/dL) 1.72±1.39 3.85±1.22 <0.001 
DDimer ng/mL 380 (315-675) 585 (250-880) 0.149 
Troponin I ng/mL 3.2 (1.7-4.8) 5.8 (3.9-8) 0.026 
ADMA (103 ng/mL) 213118 386297 0.003 
WBC 103/ μL 5.82.5 6.12.8 0.595 
Hemoglobin (g/dl) 13.51.6 12.71.6 0.019 
Neutrophil 103/ μL 3.61.6 3.91.8 0.359 
Eosinophil  1/ μL 60 (20-187) 10 (20-70) 0.033 
Lymphocyte 103/ μL 1.9170.821 1.4290.674 0.005 
Monosite 103/ μL 0.470.18 0.380.20 0.062 
Favipiravir (n/%)  9 (21.4) 33 (80.5) <0.001 
Oseltamivir (n/%) 25 (59.5) 24 (58.5) 0.928 
Azithromycin (n/%) 24 (57.1) 27 (65.9) 0.421 
Chloroquine (n/%) 39 (92.9) 32 (78) 0.056 
Vitamin C (n/%) 2 (4.8) 18 (43.9) <0.001 
Dexamethasone (or potentially 
other glucocorticoids) (n/%) 
1 (2.4) 7 (17.1) 0.023 
Tocilizumab (n/%) 0 (0) 3 (7.3) 0.076 
Convalescent plasma (n/%) 0 (0) 3 (7.3) 0.076 
Enoxaparin (n/%) 18 (42.9) 30 (73.2) 0.005 
Continuous variables are given as mean ± SD. BMI: body mass index. HT: Hypertension, HPL: Hyperlipidemia, DM: 
Diabetes Mellitus, BMI: Body Mass Index; SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, LVEF: Left 
Ventricular Ejection Fraction; CCB: Calcium Channel Blocker. ACEI: Angiotensin-converting enzyme inhibitors. ARB: 
Angiotensin II receptor blockers. ADMA: Asymmetric Dimethylarginine, WBC: White blood cell; CRP: C Reactive 
Protein. 
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had fever more frequently (61.9% vs. 33.3, 
p=0.008) compared to patients without lung 
involvement. The remaining characteristics 
including previous drugs and the presence of 
hypertension and coronary artery disease were 
not different between groups. 
Patients with lung involvement had higher 
admission glucose (133.6±60 vs. 107.422.5 
mg/dl, p=0.011), C-Reactive Protein (CRP) 
(3.85±1.22 vs. 1.72±1.39, p<0.001), and 
ADMA concentrations (386297 vs 213118, 
p=0.003), and had lower hemoglobin 
concentration (12.71.6 g/dl vs. 13.51.6, 
p=0.019) and lymphocyte count (1.4290.674 
vs. 1.9170.821 103/μl, p=0.005) compared to 
patients without lung involvement. Moreover, 
we observed a trend for decreased monocyte 
count in group 1, which did not reach statistical 
significance (p=0.062). Interestingly, only 11 
(13%) patients had normal ADMA values 
(12.35 ng/mL and 1000 ng/mL), 90.5% of 
group 1, and 83.3% of group subjects had very 
high ADMA concentrations.  We observed a 
good correlation between ADMA and CRP 
(Figure-1). As expected, patients in group 1 
received favipiravir, vitamin C, intravenous 
steroids, and anti-coagulants more frequently 
than the control subjects. Multivariate analysis 
including presence of fever, hemoglobin value, 
glucose concentration, lymphocyte count, and 
log ADMA identified log CRP concentration 
(OR= 3.047, 95% CI=1.881-5.023, p<0.001) 
as the single independent predictor for lung 


























The principal finding of this study is that the 
patients with lung involvement had higher 
ADMA concentrations with respect to those 
without lung involvement, plasma ADMA 
levels were also considerably higher than 
normal values in control group. 
Vascular endothelium is an active paracrine, 
endocrine and autocrine organ invariably 
involved in regulation of vascular tonus and 
vascular homeostasis [5]. Autopsy series of 
deceased COVID-19 patients reported direct 
viral invasion of endothelial cells and 
widespread endothelial inflammation [8]. In 
addition to endothelial dysfunction, an 
imbalance towards vasoconstriction and 
prominent microvascular pro-coagulant activity 
is frequently encountered [9]. Correspondingly, 
Table 2. Logistic regression analyze of ADMA with lung involvement and CRP. 
Parameters Univariate Multivariate 
Variables OR 95%CI p OR 95%CI p 
Lung Inv. (+) 3.333 1.284-8.653 0.013 2.070 0.571-7.502 0.268 
CRP (Log) 1.633 1.182-2.255 0.003 1.633 1.182-2.255 0.003 
 
ADMA: Asymmetric Dimethylarginine, CRP: C Reactive Protein. 
 
 
Figure 1. Relation of ADMA with lung 
involvement. 
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Micro CLOTS is defined as a complication of 
severe COVID-19 infection with obstructive 
thrombo-inflammatory involvement of lung 
capillaries, which possibly reflects an atypical 
form of acute respiratory distress syndrome 
(ARDS) [10].  
NO is a critical molecule that has a role in 
maintenance of organ perfusion and vascular 
balance [11,12]. ADMA is a protein breakdown 
product that inhibits endogenous NOS enzyme 
and thus lowers NO activity. A study involving 
critically ill patients in intensive care units 
revealed ADMA as the strongest independent 
predictor of mortality. Moreover, patients at the 
highest quartile had 17-fold increased mortality 
compared with the lowest tertile [13]. 
Therefore, ADMA accumulation has been 
proposed to be an etiologic factor that is 
involved in multiorgan failure pathogenesis due 
to decreased NO production [14].  
In this study, the patients with lung involvement 
had higher ADMA concentrations, majority of 
the study patients had considerably higher 
plasma ADMA levels than normal values. We 
think that endothelial dysfunction is invariably 
present in COVID-19 disease whether there is 
an accompanying pneumonia or not. 
Interestingly, in the Cardiovascular Risk in 
Young Finns Study, investigators followed 
1043 infection-related hospitalization in early 
childhood and documented adverse adulthood 
atherosclerotic changes 33 years later. 
Childhood infection-related hospitalization was 
closely associated with increased ADMA 
concentrations in the adulthood [15]. Although 
we don’t have a long-term follow-up data 
regarding our patient population, we may 
hypothesize that elevated ADMA levels reflect 
inflammatory response severity in our study at 
the 1st month of follow-up. 
Inflammatory response has a central role with 
increasing severity of COVID-19 disease, 
especially when cytokine storm is present. CRP 
is a non-specific acute phase reactant 
synthesized by the liver, and a biological 
marker of inflammation, infection and tissue 
damage [15].   Computed tomography is the 
main imaging method to determine the severity 
of COVID-19 pneumonia. A recent study 
revealed increased CRP concentrations in the 
early stage of COVID-19 disease and CRP was 
an independent predictor of severe lung lesion 
[16]. Similarly,  CRP in addition to interleukin 
6, was highly predictive of mechanical 
ventilation requirement [17]. We also identified 
CRP as the sole independent predictor of lung 
involvement similar to these studies. 
Increased CRP activity may cause endothelial 
dysfunction due to inhibition of NO synthesis 
and bioactivity [18].  High ADMA levels were 
closely associated with CRP, cardiovascular 
risk factors, and cardiovascular death in 
patients with newly diagnosed diabetes mellitus 
[19]. Data suggests that ADMA and CRP are 
involved in endothelial dysfunction [20,21]. 
We identified CRP as the sole determinant of 
ADMA concentration and revealed a 
correlation between these parameters in our 
study, which are in accordance with the 
aforementioned studies.  
Our study has several limitations that must be 
considered when interpreting these results, 
most importantly the small population size. We 
only have ADMA concentrations at the 1st 
month of follow-up after discharge. We lack 
serial ADMA measurement and a healthy 
control group. So, there is need for larger and 
multi-center studies which powered for 
improvement in clinical outcome (particularly 
thrombogenic events). Beyond these 
limitations, this is a pioneering study for further 
research that will focus on modalities to detect 
patients with pulmonary involvement at an 
early stage. 
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The findings of this study emphasize that 
elevated ADMA concentrations as the 
surrogate of endothelial dysfunction in 
COVID-19 patients whether they have 
pneumonia or not. And, It deserves 
consideration as a laboratory parameter for our 
better understanding of COVID-19 
physiopathology. 
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